This trial is active not recruiting!
Search for a recruiting clinical trial for your condition
You can access this
clinical trial
if you have
Systemic Lupus Erythematosus
and you are
over 18
years old
Phase
3
This is a trial in the final phase before the treatment is released on the market.
Show me locations

The purpose

This study provides subjects who complete the BEL113750 study and subjects who complete the open-label extension of HGS1006-C1115 (referred to as C1115) Study in Japan the option of continuing treatment with belimumab (10 mg/kg intravenously every 4 weeks) for those randomized to belimumab, or the option to begin treatment with belimumab for those randomized to placebo, as an add-on to their standard of care SLE therapy.

Provided treatments

  • Drug: Belimumab
Tris trial is registered with FDA with number: NCT01597622. The sponsor of the trial is GlaxoSmithKline and it is looking for 420 volunteers for the current phase.
Official trial title:
BEL114333, a Multicenter, Continuation Study of Belimumab in Subjects With Systemic Lupus Erythematosus (SLE) Who Completed the Phase III Study BEL113750 in Northeast Asia or Completed the Open-label Extension of HGS1006-C1115 in Japan